Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)
27.46
+0.25 (0.92%)
Sep 30, 2026, 3:00 PM CST
SHA:603351 Revenue
Nanjing Well Pharmaceutical Group had revenue of 383.29M CNY in the quarter ending June 30, 2026, with 18.30% growth. This brings the company's revenue in the last twelve months to 1.40B, up 9.25% year-over-year. In the year 2025, Nanjing Well Pharmaceutical Group had annual revenue of 1.34B with 2.95% growth.
Revenue (ttm)
1.40B
Revenue Growth
+9.25%
P/S Ratio
2.65
Revenue / Employee
1.95M
Employees
718
Market Cap
3.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.34B | 38.28M | 2.95% |
| Dec 31, 2024 | 1.30B | 140.91M | 12.19% |
| Dec 31, 2023 | 1.16B | 44.83M | 4.03% |
| Dec 31, 2022 | 1.11B | 68.70M | 6.59% |
| Dec 31, 2021 | 1.04B | 306.24M | 41.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Starry Pharmaceutical | 2.46B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Huaren Pharmaceutical | 1.30B |
| Qianjiang Yongan Pharmaceutical | 979.49M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 737.90M |
| Nanjing Hicin Pharmaceutical | 726.62M |
| Zhejiang Yatai Pharmaceutical | 328.58M |
| Hainan Shuangcheng Pharmaceuticals | 309.80M |